Considering Personalized Interferon Beta Therapy for COVID-19

Davoudi-Monfared et al. (1) report in this journal the results from a clinical trial on coronavirus disease 2019 (COVID-19) patients showing that subcutaneous administration of interferon beta (IFN-β) was associated with more rapid recovery severe acute respiratory syndrome 2 (SARS-CoV-2) infection and decreased mortality. These findings have been corroborated by two recent phase trials during which IFN-β administered, either combination lopinavir-ritonavir ribavirin (2) or alone nebulized, inhaled form molecule (3). Recombinant therapy, lopinavir-ritonavir, also reduced mortality recently completed randomized hospitalized Middle East (MERS) (4). reports provide rationale for therapy infections syndromes, together finding an impaired type I IFN signature COVID-19 (5).